Since recombinant soluble ACE2 proteins can block SARS‐CoV‐2 infection by competitively inhibiting the binding of SARS‐CoV‐2 to ACE2‐expressing cells in vitro [88, 89], EVs equipped with ACE2 may limit the progression of viral infection in vivo [51, 87]. The gene discussed is ACE2; the disease is viral infectious disease.